COMMUNIQUÉS West-GlobeNewswire
-
NeuroSalt Claims Evaluated: What the Pink Salt Trick Research Says About Neuro Salt Supplementation for Nerve Health
31/03/2026 -
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
31/03/2026 -
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
31/03/2026 -
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
31/03/2026 -
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/03/2026 -
Stage4Hope™ Commits $2.5 Million to Memorial Sloan Kettering Cancer Center to Accelerate Breakthrough Cancer Research
31/03/2026 -
Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)
31/03/2026 -
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
31/03/2026 -
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
31/03/2026 -
UPDATE - Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026 -
Fagron increases share capital through exercise subscription rights
31/03/2026 -
Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress
31/03/2026 -
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026 -
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026 -
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026 -
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation
31/03/2026 -
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026 -
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026
Pages